H2 2020 Pipeline Review for Cerebral Palsy – Snapshot of the Global Therapeutic Landscape – ResearchAndMarkets.com

December 21, 2020 Off By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Cerebral Palsy – Pipeline Review, H2 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

The publisher’s latest Pharmaceutical and Healthcare disease pipeline guide provides an overview of the Cerebral Palsy (Central Nervous System) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cerebral Palsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cerebral Palsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cerebral Palsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 1, 1, 7, 1 and 1 respectively. Similarly, the Universities portfolio in Phase 0 and Preclinical stages comprises 1 and 1 molecules, respectively.

Cerebral Palsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cerebral Palsy (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Cerebral Palsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. (Read more…)
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cerebral Palsy (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cerebral Palsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cerebral Palsy (Central Nervous System)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cerebral Palsy (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cerebral Palsy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

1. Introduction

  • Report Coverage

2. Cerebral Palsy – Overview

3. Cerebral Palsy – Therapeutics Development

  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes

4. Cerebral Palsy – Therapeutics Assessment

  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type

5. Cerebral Palsy – Companies Involved in Therapeutics Development

  • Baylx Inc
  • BrainRepair UG
  • Cell Tech Pharmed Co
  • CytoDel Inc
  • FamiCord Group
  • Gene Techno Science Co Ltd
  • Help Therapeutics
  • Hope Biosciences LLC
  • iCELL Biotechnology Co Ltd
  • Kashiv BioSciences LLC
  • Meridigen Biotech Co Ltd
  • MGC Pharmaceuticals Ltd
  • Revance Therapeutics Inc

6. Cerebral Palsy – Drug Profiles

  • ANGES-001 – Drug Profile
  • BXU-007 – Drug Profile
  • Cell Therapy for Neurology – Drug Profile
  • CepaCann – Drug Profile
  • Cyto-012 – Drug Profile
  • K-128 – Drug Profile

7. Cerebral Palsy – Dormant Projects

8. Cerebral Palsy – Product Development Milestones

  • Featured News & Press Releases
  • May 01, 2020: Revance and Mylan biosimilar to Botox program decision to extend beyond April 30, 2020

9. Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/rqfedh



Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900